A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
NCT00230529 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 249
Last updated 2011-06-09
Summary
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.
Conditions
Interventions
- DRUG
Sponsors & Collaborators
-
Centocor, Inc.
lead INDUSTRY
Principal Investigators
-
Centocor, Inc. Clinical Trial · Centocor, Inc.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Completion
- 2003-01-31
More Related Trials
-
Bimekizumab in Plaque Psoriasis
NCT06336343 ·Status: COMPLETED ·Phase: PHASE4
-
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03410992 ·Status: COMPLETED ·Phase: PHASE3
-
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)
NCT00254982 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Long-Term Infliximab for Psoriasis (P05319)
NCT00779675 ·Status: COMPLETED
-
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
NCT02905006 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
NCT03025542 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
NCT02969525 ·Status: COMPLETED ·Phase: PHASE2
-
Psoriasis Longitudinal Assessment and Registry
NCT00508547 ·Status: ACTIVE_NOT_RECRUITING
-
Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)
NCT00833053 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
NCT06591273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept
NCT00527072 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
NCT02207244 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
NCT03010527 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
NCT00629772 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
NCT05020249 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
NCT00267969 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
NCT02905331 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
NCT02513550 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)
NCT01225731 ·Status: COMPLETED ·Phase: PHASE2
-
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
NCT03885089 ·Status: COMPLETED
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
NCT03230292 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
NCT05003531 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
NCT01729754 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis
NCT05499416 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
NCT01010542 ·Status: TERMINATED ·Phase: PHASE1